Role of inhaled corticosteroids in the management of COPD;Rola wziewnych kortykosteroidów w leczeniu POChP

Pneumonologia i Alergologia Polska

Volumn 77, Issue 2, 2009, Pages 186-191

  Chazan, Ryszarda ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69849096457     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, Global strategy for the diagnosis management and prevention of COPD Available from http://www.goldcopd.com/ /ACCES Augast 5 2008.
2. Barnes P.J. Mediators of chronic pulmonary disease. Pharmacol. Rev. 2004; 56: 515-548.
3. Wagner A., Howarth G., Brieve J.L. Nongenomic actions of glucocorticosteroids on the airway vasculature in astma. Proc. Am. Thor. Soc. 2004; 1: 235-238.
4. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - New mechanisms for old drugs. N. Engl. J. Med. 2005; 353: 1711-1723.
5. Pauwels R.A., Loefdahl C.G., Laitinen L.A. i wsp. ERS Society Study on COPD. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking N. Engl. J. Med. 1999; 340: 1948-1953.
6. Barnes P.J, Reduced, histone deacetylase in COPD. CHEST 2006; 129: 151-155.
7. Ito K., Lim S., Caramori G. i wsp. Cigarette smoking reduces histone deacetylase 2-expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages FASEBJ 2001; 15: 1100-1102.
8. Culpitt S.V., Nightingale J.A., Barnes P.J. i wsp. Effect of high dose inhaled corticosteroid on cells, cytokines and. proteases in induced sputum in COPD. Am. J. Respir. Crit. Care Med. 2003; 167:24-31.
9. Donaldson G.C., Seemungal T.A., Paul E.A. Effect, of exacerbation on quality of life in patients with COPD. Am. J. Respir. Crit. Care Med. 1998, 157: 1418-1422.
10. Donaldson G.G., Seemungal T.A., Bhownik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in COPD. Thorax 2002; 57: 847-852.
11. Sin D.D., Tu J.V. Inhaled corticosteroids and. the risk of mortality and readmission in elderly patients with COPD. Am. J. Respir. Crit. Care Med. 2001; 164: 580-584.
12. Soler-Cataluna J.J., Martinez Garcia M.A., Roman Schanzez P. i wsp. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
13. Calverley P.M., Pauwels R., Vestbo J. i wsp. Withdrawal from treatment as an outcome of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919.
14. Szafranski W., Cukier A., Ramirez A. i wsp. Efficacy and safety of budesonid/formoterol in the managemant of COPD, Eur, Respir. J. 2003; 21: 74-81.
15. Calverley P.M., Andersen J.A., Celli B. i wsp. Efficacy of salmeterol anf fluticasone propionate on mortality in COPD The TORCH survival trial. New Engl. J. Med. 2007; 356: 775-789.
16. Sin D.D., Wu L., Andersen J.A. i wsp. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 80: 992-997.
17. Gartlehmer G., Hansen R.A., Carson S.S., Lohr K.N. Efficacy and safety of inhaled corticosteroids in patients with COPD. A systemic review and meta-analysis of health outcomes. Ann. Farm. Med. 2006; 4: 253-262.
18. Barnes P.J. Anti-inflammatory effects of salmetrol/fluticasone propionate in chronic obstructive lung disease. Eur. Respir. J. 2007; 29: 587-595,
19. Bourbeau J., Christodoupoulos P., Maltais F. i wsp. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD; a randomized controlled trial. Thorax 2007; 62: 938-943.
20. Soriano J.B., Kiri V.A., Pride N.B., Vesto J. Inhaled corticosteroids with/without long-acting beta-agonist reduce the risk of re-hospitalization and. death in COPD patients. Am. J. Respir. Med. 2003; 2: 67-74.
21. Mapel D.W., Hurley J.S., Roblin D. i wsp. Survival of COPD patients using inhaled corticosteroids and. long-acting beta agonists. Respir. Med. 2006; 100: 595-609.
22. Nannini L.J. Cochrane Database Syst. Rev. 2007; issue 3: Art. No CD003794 DOI:10-1002/14651858CD 003794.
23. Nannini L.J. Cochrane Database. Syst. Rev. 2007; issue 4: Art. No: CD006826 DOL10-1002/14651858CD 006829.
24. Vestbo J. TORCH Study Group The TORCH (TOwards a Revolution in COPD Health) survival, study protocol. Eur. Respir. J. 2004; 24: 206-210.
25. Calverley P.M., Anderson J.A., Celli B. i wsp. Efficacy of salmeterol and fluticasone propionate on mortality in chronic obstructive pulmonary disease TORCH survival trial. N. Engl. J. Med. 2007; 356: 775-789.
26. Celli B., Thomas N.E., Anderson J.A. i wsp. Effect of pharmacotherapy on rate of decline of lung function in COPD. Results from TORCH study. Am. J. Respir. Crit. Care Med. 2008, 178: 332-338.
27. Wedzicha J., Calverley P., Seemungal T.A. i wsp. The prevention of chronic obstructive pulmonary disease exacerbations by Salmeterol/fluticasone propionate or tiotropium bromide. The INSPIRE trial. Am. J, Respir. Crit. Care Med. 2008; 177: 19-26.
28. Aaron S., Vandemheen K.L., Fergusson D. i wsp. Canadian Thoracic Society /Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol or fluticasone-salmetrol for treatment of chronic obstructive pulmonary disease a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.
29. Ernst. P., Gonzales A.V., Brassard. P, Suisse S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and. risk of hospitalization. Am. J. Respir. Crit. Care Med. 2007; 176: 162-166.
30. Rabe K.F. Treating COPD The TORCH trial. P value. N. Engl. J. Med. 2007; 356: 851-854.
31. Hole D.J., Watt G.C., Davey-Smith G. i wsp. Impaired lung function and. mortality risk in men and. women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-715.
32. Löfdahl C.-G., Postma D.S., Pride N.B. i wsp. Possible protection by inhaled budesonide against ischaemic cardiec events in mild COPD. Eur. Respir. J. 2007; 29: 1115-1119.
33. Sin D.D., Man J.P., Man S.F. The risk of osteoporosis in Caucasien men end. women with obstructive airways disease, Am. J. Med. 2003; 114: 10-14.
34. McEvoy CE., Ensrud K.E., Bender E. i wsp. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary diseese. Am. J. Resp. Crit. Care Med. 1998; 157: 704-709.
35. Todd A., Pickard S., David H. Risk for death associated with medications for recently diagnosed, chronic obstructive pulmonary disease. Ann. Intern. Med. 2008; 149: 380-390.